Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

Abstract

In this 24-week trial, reduction of neutrophil serine protease activity with brensocatib in patients with bronchiectasis was associated with improvements in bronchiectasis clinical outcomes. (Funded by Insmed; WILLOW ClinicalTrials.gov number, NCT03218917.).